Articles from Broken String Biosciences
Broken String Biosciences, a leader in advancing gene editing safety, and BioLizard, an expert in scientific data analytics and AI, today announced the development of SafeGuide, an AI tool for selecting safer, better guide RNAs (gRNA), the gene editing element that tells tools like CRISPR where to repair DNA. With SafeGuide, developers of next-generation gene-edited therapies will be able to quickly find the ideal gRNA with less reliance on time-consuming and expensive wet lab testing, helping to replace current trial-and-error approaches that often take one to two years and result in drug costs of $4 million and more per patient.
By Broken String Biosciences · Via Business Wire · July 10, 2025

Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP) for developers of gene-edited therapies that allow for the detection of on- and off-target edits at high resolution, in days, in their own labs. The program allows select companies to use Broken String’s INDUCE-seq® platform as a first-of-its-kind offering for rapidly detecting on-target and off-target effects that can occur during gene editing. This new on-demand offering enables gene editing therapy developers to assess on- and off-target effects in days, as opposed to months.
By Broken String Biosciences · Via Business Wire · February 6, 2025

Broken String Biosciences (“Broken String”), a genomics company enabling development of the next generation of more precise, safe, and effective cell and gene therapies, today announced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) of its Board of Directors.
By Broken String Biosciences · Via Business Wire · September 23, 2024

Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive, Steve will guide the expansion of the Company’s commercial operations and implement a robust go-to-market strategy for its Next-Generation Sequencing (NGS)-based DNA break-mapping platform, INDUCE-seq®, as the Company looks to strengthen its position across key markets.
By Broken String Biosciences · Via Business Wire · July 24, 2024

Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has entered a research collaboration with the Francis Crick Institute, a world-leading biomedical discovery institute dedicated to understanding the biology underlying health and disease.
By Broken String Biosciences · Via Business Wire · May 7, 2024

Broken String Biosciences (“Broken String”), a genomics company that has built a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the appointment of Gavin Burns, PhD, as Vice President of Quality and Operations. With an extensive background leading quality assurance in the genomics sector, Gavin will be responsible for building and optimizing Broken String’s teams, processes, and systems. His appointment will enable the Company to develop and scale its Next Generation Sequencing (NGS)-based DNA break-mapping platform, INDUCE-seq™, furthering the technology’s capabilities in supporting gene-editing applications.
By Broken String Biosciences · Via Business Wire · November 22, 2023

Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that its INDUCE-seq™ DNA break-mapping technology had been used in a peer-reviewed research paper to characterize off-target effects of CRISPR-Cas9 gene editing resulting from changes in DNA topology1. Published in Molecular Cell, the research highlights DNA topology as a key regulator to CRISPR targeting specificity that must be carefully considered during development of CRISPR-based therapies.
By Broken String Biosciences · Via Business Wire · October 18, 2023

Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the expansion of its senior leadership team with the appointments of Vincent Smith, PhD, as Chief Technology Officer and Jessica Rich as VP Business Development. Bringing significant expertise in their respective fields, Vincent and Jessica’s appointments are a key part of Broken String’s strategy to deliver on its Series A goals, which include the continued development of its INDUCE-seq™ DNA break-mapping platform and acceleration of its commercial expansion across global markets.
By Broken String Biosciences · Via Business Wire · October 2, 2023

Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from HERAN Partners, and existing investors Tencent and Dieter von Holtzbrinck Ventures (DvH Ventures). As part of the round, Yoann Bonnamour, Mérieux Equity Partners, and Arnaud Autret, Illumina Ventures, join the Company’s Board of Directors.
By Broken String Biosciences · Via Business Wire · September 18, 2023